接受微小隐孢子虫免疫疗法的癌症患者体内的补体激活。
Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
作者信息
Biran H, Moake J L, Reed R C, Gutterman J U, Hersh E M, Freireich E J, Mavligit G M
出版信息
Br J Cancer. 1976 Nov;34(5):493-9. doi: 10.1038/bjc.1976.203.
Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.
对26例播散性癌症患者进行了血清补体水平检测，这些患者接受了小棒状杆菌输注免疫治疗。46%的患者出现补体激活，表现为C3或C4或两者消耗。血清样本显示C3降低与C3前活化剂转化之间存在直接相关性，而当仅C4降低时未发生这种转化。结论是，在检测到C3消耗的患者中旁路（备解素）途径被激活，而在C4消耗但C3未降低的患者中经典（C1）途径被激活。观察到对回忆抗原的迟发型皮肤超敏反应与小棒状杆菌相关补体激活的发生率之间存在直接相关性。
Zotero 插件